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Advances in Critical Care and Emergency Medicine 
 
Emanuela Keller, Kyra L. Becker 
 
Of the many publications in this field, the following appear to be most relevant for  
clinical practice. 
 
Ischemic Stroke 
Intravenous thrombolysis with tissue plasminogen activator (tPA) is the only therapy 
proven to improve outcome in ischemic stroke. Studies of intravenous thrombolysis 
show that therapy response is time dependent; the sooner patients receive tPA after 
stroke onset, the better the chance of good outcome.{Marler, 2000 #393;Lees, 2010 
#372}  The required brain imaging before tPA administration and further 
imponderables delay the therapy initiation. In the Pre-Hospital Acute Neurological 
Treatment and Optimization of Medical Care in Stroke (PHANTOM-S) pilot study, 
Weber and colleagues attempt to speed up the process by administering tPA prior to 
hospital arrival. {Weber, 2013 #366}  If patients with a high probability of stroke 
contacted the emergency medical system within 4 hours after symptom onset, a 
stroke emergency mobile unit (STEMO) equipped with a CT scanner was dispatched.  
Brain imaging was performed at the scene (along with point of care blood work) 
enabling tPA administration in the STEMO. For STEMO patients the median time 
between emergency call and tPA initiation was 58 minutes (5-63), for a group of 
historic controls 92 (79-112).  The PHANTOM-S study was a non-randomized pilot 
study done in urban Germany (Berlin).  A randomized controlled study done in a 
more rural region of Germany (Homburg) showed a similar relative time decrease 
when using a CT-equipped STEMO, while the initiation of tPA therapy after 
emergency notification occurred more quickly in both groups.{Walter, 2012 #360} 
Both studies suggest that a CT-equipped STEMO decreases the time to tPA 
administration, which may be of significant clinical benefit.   
 
Hyperglycemia is associated with worse stroke outcome, but there is no evidence 
that strict glucose control improves outcome.{Kruyt, 2010 #499}  In a proof of concept 
study to determine if aggressive glucose management could attenuate infarct growth, 
patients with carotid territory strokes were randomized to intensive insulin therapy 
(IIT; N=87) or standard (subcutaneous) insulin therapy (SIT; N=89) within 6 hours 
after symptom onset.{Rosso, 2012 #404}  In the IIT group, insulin was administered 
as a continuous infusion with a goal glucose <7 mmol/L (<126 mg/dL) for a duration 
of  24 hours. MRIs were obtained within 5 hours after onset (before randomization) 
and again after therapy cessation (1 to 3 days after stroke onset).  While the IIT 
regimen improved glucose control, it was associated with increased infarct growth. 
The IIT regimen was also associated with increased hypoglycemia episodes. Clinical 
outcomes were similar between the treatment groups. The ongoing Stroke 
Hyperglycemia Insulin Network Effort (SHINE) Trial opts for a similar glucose goal 
(80-130 mg/dL) but allows for 12 hours between symptom onset and treatment 
onset.{Southerland, 2012 #420}  Unless the results of SHINE suggest otherwise, the 
data abundance suggests that intensive insulin therapy in acute stroke is of no 
benefit and may cause harm.{Bellolio, 2011 #448} 
 
 
Intracerebral Hemorrhage 
Formatiert: Englisch (USA)
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After INTERACT1, the larger INTERACT2 trial aimed at investigating whether rapid 
lowering of blood pressure (target systolic level <140 mm Hg within 1 hour of 
randomization and maintained for 7 days) {Anderson, 2013 #7} improves the 
outcome in patients with intracerebral hemorrhage (ICH) compared to current 
guideline-recommended treatment (target systolic level of <180 mm Hg) 
{Morgenstern, 2010 #8}. Patients were treated within 6 hours after symptom onset; 
exclusion criteria included structural bleeding causes, deep coma (median GCS 14), 
massive hematomas (median volume 11 cc), poor prognosis and plans for immediate 
surgery.  Among 2794 patients for whom the primary outcome (modified Rankin 
Scale) after 90 days could be determined, average blood pressure at enrollment was 
179/101 mmHg. Systolic blood pressure after 1 hour and 6 hours treatment was 150 
mmHg and 139 mmHg with intensive therapy versus 164 mmHg and 153 mmHg with 
conventional treatment. The primary outcome (death or major disability) was not 
different between groups. The ordinal analysis of modified Rankin scores, however, 
indicated that participants in the intensive treatment group had significantly improved 
functional outcomes with better overall health-related quality (EQ-5D score; 
P=0.002). Several limitations of INTERACT2 are noted, among them e.g. the fact that 
antihypertensive medication was not standardized in the acute phase and that clinical 
management probably differed among participating centers. The ongoing trial ATACH 
II will provide further data on intensive lowering of blood pressure within 4.5 hours 
using intravenous nicardipine.{Qureshi, 2011 #9} Despite the negative primary 
endpoint, INTERACT2 shows that rapid blood pressure lowering is safe and may 
improve functional outcome in a selected subgroup of patients with relatively mild 
symptoms/small hemorrhages. Targeting systolic blood pressure values <140 mm Hg 
is justifiable in this specific patient population with spontaneous non-structural ICH.  
 
The Surgical Trial in Lobar Intracerebral Hemorrhage (STICH) II compared early 
surgery with initial conservative treatment in an international, multicenter, 
prospective, randomized trial.{Mendelow, 2013 #15}  Only conscious patients with 
superficial lobar intracerebral hemorrhage of 10-100 mL and no intraventricular 
hemorrhage, admitted within 48 hours after symptom onset, were included. In the 
group randomized to initial conservative treatment, delayed evacuation was permitted 
if judged clinically appropriate. Of the 601 patients enrolled, 307 were randomly 
assigned to early surgery and 294 to initial conservative treatment. Unfavorable 
outcome (based on extended Glasgow Outcome Score) was seen in 59% of the early 
surgery group patients and in 62% of the initial conservative treatment group (OR 
0.86; P=0.367).  Eventually, 21% of the patients randomized to initial conservative 
treatment underwent surgery. The absence of a significant difference between the 
groups may be related to the heterogeneous patient population (i.e. hematoma 
volumes ranging from 10-100 mL), a high crossover rate from initial conservative 
treatment to surgery and the lack of standardized procedures for both the surgical 
intervention and the conservative treatment. Early surgery may be only one important 
piece in the treatment of patients with ICH. The ongoing Clot Lysis Evaluating 
Accelerated Resolution of Intraventricular Hemorrhage (CLEAR-IVH) and Minimally 
Invasive Surgery plus tPA for ICH Evacuation (MISTIE) trials will show whether 
minimal invasive techniques will play a role in the treatment of subsets of ICH 
patients. 
 
Cardiac Arrest 
Since two seminal studies showed that hypothermia improves outcome, hypothermia 
is part of the standard treatment of patients with cardiac arrest due to ventricular 
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fibrillation (VF).{Bernard, 2002 #852;, 2002 #881}  It has been hypothesized that 
earlier cooling would be associated with better outcome. In a study by Kim and 
colleagues, patients with cardiac arrest were randomized to pre-hospital cooling with 
infusion of chilled (4oC) saline versus standard of care over a 5 year period.{Kim, 
2013 #750}  The study included all patients with cardiac arrest regardless of initial 
rhythm. Goal temperature for cooling was ≤34oC. The primary analysis included 1359 
patients.  For patients who also received hospital cooling, administration of cooled 
saline in the pre-hospital setting, reduced the time to goal temperature by over an 
hour (4.2 hours versus 5.5 hours; P<0.001).  Pre-hospital cooling, however, did not 
result in decreased mortality or improved neurological outcome at the time of hospital 
discharge. Besides, these patients were also more likely to suffer a re-arrest and 
have evidence of pulmonary edema upon hospital admission. A separate study 
actually questions the benefit of hypothermia treatment in patients with out of hospital 
cardiac arrest.{Nielsen, 2013 #768}  In a randomized controlled study comparing two 
temperature goals, Nielsen and colleagues found no decrease in mortality or 
improvement in neurological outcome in patients randomized to hypothermia (33oC) 
compared to those where the focus was to avoid fever (36oC). Overall, these trials 
suggest that decreasing the time to achieve hypothermia, i.e. earlier cooling confers 
no benefit. Moreover, the benefit of hypothermia itself is questioned.  Further studies 
will be needed to determine the true value of hypothermia, appropriate temperature 
targets and the duration of therapy. 
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